Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01530581 |
Recruitment Status :
Completed
First Posted : February 10, 2012
Last Update Posted : August 10, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Transplantation for Hematologic Malignancies | Procedure: G-PB Transplant Procedure: G-BM Transplant | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 230 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies |
Study Start Date : | November 2008 |
Actual Primary Completion Date : | June 2012 |
Actual Study Completion Date : | June 2014 |
Arm | Intervention/treatment |
---|---|
Experimental: G-BM Transplant |
Procedure: G-BM Transplant
G-BM Transplant |
G-PB Transplant
G-PB Transplant
|
Procedure: G-PB Transplant
G-PB Transplant |
- Efficacy [ Time Frame: 2 years ]The use of G-BM is associated with a longer time to treatment failure (extensive chronic GVHD, relapse, death) than is the use of G-PB for adult myeloablative allogeneic transplantation for hematologic malignancies.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 16 Years to 65 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Recipient must
- Be between the ages of 16 and 65 years old
-
Have one of the following hematologic malignancies:
- Acute myeloid leukemia (de novo, secondary or therapy related) in untreated 1st relapse or in remission or with evidence of molecular relapse but blasts less than 5%
- Chronic myeloid leukemia in chronic or accelerated phase (de novo or therapy related)
- Myelodysplasia (de novo or therapy related)
- Other hematologic malignancy (de novo or therapy related) including but not limited to: ALL (CR 1, CR2 or CR3), CLL, non-Hodgkin's lymphoma, Hodgkin's lymphoma
- Must be receiving a myeloablative conditioning regimen of busulfan and cyclophosphamide or TBI and cyclophosphamide or other myeloablative regimen approved by the Clinical Study Chair. (Regimens containing ATG are not allowed.)
- Have an HLA-identical sibling donor
- Meet the transplant centre's criteria for myeloablative allogeneic transplantation*
- Have an ECOG performance status of 0, 1 or 2
- Have given signed informed consent
Donor must
- Be 18 years of age or older. (Upper age limit is at the discretion of the transplant physician at the collection centre.)
- Be able to undergo general anesthesia and BM harvest or peripheral blood collection as per assessment by a transplant physician. (If an anesthetist assesses a donor after randomization and determines the donor should not undergo general anesthesia, then the donor and recipient will be withdrawn from the study.)
- Be a sibling of the recipient
- Be a 6/6 HLA match of the recipient. HLA typing is by serologic or DNA methodology for A and B and by DNA methodology for A and B and by DNA methodology for DRB1 (intermediate resolution)
- Have given signed informed consent
Exclusion Criteria
Recipient
1. The recipient is HIV antibody positive
Donor
- The donor is unable to undergo general anesthesia, bone marrow harvest or peripheral blood collection
- The donor is pregnant or breastfeeding at the time of progenitor cell collection
- The donor has a history of malignant disease within the last 5 years or current malignancy other than non-melanomatous in situ skin carcinoma or cervical carcinoma in situ
- The donor is HIV antibody positive
- The donor has a known sensitivity to E. coli-derived products
- The donor and recipient are identical twins

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01530581
Saudi Arabia | |
King Faisal Specialist Hospital & Research Center | |
Riyadh, Saudi Arabia, 11211 |
Principal Investigator: | Mahmoud Al Jurf, MD | King Faisal Specialist Hospital & Research Center |
Responsible Party: | King Faisal Specialist Hospital & Research Center |
ClinicalTrials.gov Identifier: | NCT01530581 |
Other Study ID Numbers: |
2081-076 |
First Posted: | February 10, 2012 Key Record Dates |
Last Update Posted: | August 10, 2018 |
Last Verified: | August 2018 |
Neoplasms Hematologic Neoplasms Neoplasms by Site Hematologic Diseases |